Dear Authors,
If you believe that your paper was mistakenly rejected by other leading journals and you do not agree with final decision, the editors of Reports of Practical Oncology and Radiotherapy offer new fast track review. You may submit your manuscript to Reports of Practical Oncology and Radiotherapy together with all prior peer-reviews obtained from the other journal and your rebuttal letter. We guarantee review based decision within 72 hours from the time we will receive your manuscript.

Fast track submission process: Please submit the manuscript with all reviews and rebuttal letter by email to Dr. Michal Masternak ( for fast review processing. To assure immediate attention the email title must to include: RPOR-fast track- Last Name First Name (of corresponding author).

Volume 12, Number 4, 2007

Effects of active form of EGFR on disease-free survival in ovarian cancer women

Wiesława Bednarek, Bartłomiej Barczyński, Danuta Skomra, Adrianna Kondracka, Jan Kotarski


Background: Standard procedure in cases of ovarian cancer includes surgical treatment and
complementary chemotherapy based on taxanes and platinum compounds. The results of such a procedure in advanced forms of cancer are still unsatisfactory. More accurate determination of the duration of remission with cancer patients is possible through the identifi cation of prognostic factors. Currently adopted and extensively used prognostic factors include, among others, the age of the patient at the moment of the disease being diagnosed, the degree of clinical advancement, the size of the tumour remaining after surgery, the histological type of the neoplasm, and the volume of fl uid in the peritoneal cavity. Among neoplasm markers the greatest importance is attributed to the CA 125 antigen, but
continued efforts are being made in the search for new, more specifi c and sensitive
Aim: The objective of the study presented herein was estimation of the prognostic signifi
cance of the active form of EGFR in the serum of women with ovarian cancer in relation to their disease-free survival time.
Materials/Methods: The study was performed on 100 women treated for ovarian cancer in the course of four years. The concentration of the active form of EGFR was determined in
the blood serum, prior to treatment, using commercial immunoenzymatic sets.
Disease-free survival was defi ned as the time elapsed from the completion of complementary first-line chemotherapy till the appearance of clinical and/or biochemical
(CA 125>30 U/ml) symptoms of relapse of the neoplastic disease.
Results: The concentration of the active form of EGFR fell within the range of 0.093–0.475 fmol/ml and did not show statistical signifi cance with relation to disease-free time: the duration of the remission period was similar in patients with low as well as with high concentration of the active form of that receptor.
Conclusions: Examination of concentration of the active form of EGFR in blood serum prior
to surgery does not display prognostic signifi cance for prediction of the length of the period of remission or of disease-free survival.

Signature: Rep Pract Oncol Radiother, 2007; 12(4) : 225-229


« back


Indexed in: EMBASE®, the Excerpta Medica database, the Elsevier BIOBASE (Current Awareness in Biological Sciences) and in the Index Copernicus.